Editorials

You have full text access to this OnlineOpen article

The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?†‡

  1. Ester Vanni,
  2. Elisabetta Bugianesi§,*

Article first published online: 22 APR 2009

DOI: 10.1002/hep.23036

Issue

Hepatology

Hepatology

Volume 49, Issue 6, pages 1790–1792, June 2009

Additional Information

How to Cite

Vanni, E. and Bugianesi, E. (2009), The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?. Hepatology, 49: 1790–1792. doi: 10.1002/hep.23036

Author Information

  1. Division of Gastro-Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy

  1. §

    fax: +39-011-6335927

*Gastro-Epatologia, Università di Torino, Azienda Ospedaliera San Giovanni Battista, Corso Bramante 88, I-10126 Torino, Italy

  1. †

    See Article on Page 1877

  2. ‡

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 22 APR 2009
  3. Accepted manuscript online: 22 APR 2009 12:00AM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (61K)

References

  • 1
    DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittman BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83: 460–469.
  • 2
    Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681–687.
  • 3
    Brun P, Catsagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518–G525.
  • 4
    Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206–211.
  • 5
    Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 22: 291–299.
    Direct Link:
  • 6
    Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18: 371.
  • 7
    Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease (NAFLD). HEPATOLOGY 2009; doi:10.1002/hep.22848.
    Direct Link:
  • 8
    Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557–2562.
  • 9
    Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002; 49: 1582–1586.
  • 10
    Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718–15723.
  • 11
    Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070–11075.
  • 12
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity fro energy harvest. Nature 2006; 444: 1027–1031.
  • 13
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature 2006; 444: 1022–1023.
  • 14
    Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–1772.
  • 15
    Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983–992.
  • 16
    Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219–1223.
  • 17
    Kaput J, Dawson K. Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction? Mutat Res 2007; 622: 19–32.
  • 18
    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015–3026.
  • 19
    Cani PD, Bibiloni R, Knauf C, Waget A, Meyrinck A, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470–1481.
  • 20
    Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374–2383.
  • 21
    Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003; 37: 343–350.
    Direct Link:
  • 22
    Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416–2426.
View Full Article with Supporting Information (HTML) Get PDF (61K)